Tauklarify imaging is a PET scan that finds tau tangles, twisted tau proteins tied to Alzheimer's, in adults with cognitive impairment evaluated for Alzheimer's. In 2026 clinic access and coverage were still limited, so bring questions about diagnosis, treatment and trial eligibility.
The FDA approved Tauklarify on Aug. 14, 2026 for this use, according to the FDA approval notice. It is the second FDA-cleared tau PET tracer for Alzheimer's, after Tauvid in May 2020, according to Breakout Biotech Stocks in its approval report.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who the scan is for
- How well does it detect tau?
- What the appointment involves
- Access and cost in 2026
- Follow-up questions to ask
Who the scan is for
The scan is for adults with cognitive impairment who are being evaluated for Alzheimer's. It detects tau neurofibrillary tangle pathology, a hallmark change that helps stage disease. Appropriate use is narrow.
The 2025 Alzheimer's Association/SNMMI criteria, summarized by HelpDementia in its AUC summary, state amyloid and tau PET fit only when doctors suspect Alzheimer's and results will directly change care. A memory clinic should explain what decision your result would change before ordering the scan. If the result would not change diagnosis, treatment or trial planning, the scan is likely not appropriate.
How well does it detect tau?
Approval rested on two studies with 617 people and five blinded readers, according to Pharmacy Times in its approval summary. Positive agreement ranged from 68% to 88% while negative agreement ranged from 93% to 99%, with strong reader agreement. Pharmacy Times reports interreader reliability was strong, with Fleiss kappa around 0.86 to 0.92.
The label still warns of misdiagnosis risk because testing focused mainly on amyloid-negative unimpaired people versus amyloid-positive impaired people. A negative scan does not exclude tau pathology and a positive scan does not confirm it. Use the result as one piece of evidence with exam, cognitive testing and amyloid status.
What the appointment involves
Pharmacy Times reports safety data in 1,734 participants showed headache in 0.7% and nausea in 0.2%. The scan uses a radioactive tracer, so staff follow radiation handling steps. Your team will explain hydration, voiding and medication steps.
Labeling calls for drinking water and urinating often after the dose as directed. It also calls for avoiding CYP1A2 inducers including tobacco for 7 days before the scan. Practical preparation helps the day run smoothly:.
- follow hydration and voiding instructions closely
- report tobacco use and prescription, over-the-counter and herbal products
- pause breastfeeding for 4 hours after the dose if applicable
Access and cost in 2026
Lantheus said it would keep supporting drug-company research programs while assessing the path to broader commercial availability, according to Launch IQ. That meant routine memory-clinic supply was not established at approval. No U.S.
list price, Tauklarify-specific billing code or coverage policy had been published at approval, according to Launch IQ and PatientSpotlight. Tau PET is offered at fewer centers than amyloid PET, with narrower Medicare and uneven commercial reimbursement. Call the imaging center before scheduling. Ask whether the tracer is stocked, whether prior authorization is required and what the self-pay charge would be.
Follow-up questions to ask
Ask how tau results combine with amyloid results. The HelpDementia summary of appropriate-use criteria points patients to ask how both results affect diagnosis, trial or therapy eligibility and prognosis.
Bring these specific questions to the visit: Bring a current medication list, tobacco-use history and lactation status. Those details affect scheduling, interpretation and aftercare instructions.
- Will tau plus amyloid results change my diagnosis or stage?
- Do results affect eligibility for trials or approved therapies?
- What do results mean for prognosis, safety planning and follow-up?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
